Advancing Biomedical Science

The Laboratory for Clinical Biochemistry Research (LCBR) focuses on understanding risk factors for heart disease, stroke, venous thrombosis, obesity, diabetes, aging, and frailty using a wide variety of assays in population and family-based research settings, particularly in the areas of coagulation, fibrinolysis, thrombosis, inflammation, and immune system function. These results are linked to animal model studies, especially research in murine atherosclerosis

Image of the Colchester Research Facility

Clinical Studies

The Laboratory research portfolio includes molecular and genetic epidemiology family-based genetic research, clinical trials and basic studies using murine models of disease.

Dr. Olson removing samples from one of the LCBR freezers.

Technical Information

The LCBR Faculty and staff has accumulated a vast amount and diverse range of experience working with and developing multitudes of clinical assays, including information regarding Luminex Overview, and Luminex Data by Analyte.

Drs. Cushman and Zakai discussing research

Collaborations

The Laboratory staff have collaborated on a wide variety of clinical studies, clinical trials, and epidemiology studies on local, national, and international scales.

Faculty Spotlight

Mary Cushman, M.D.

VCCBH Symposium Highlights Early Career Investigators, Innovative Multidisciplinary Research

 

More than 100 in-person and dozens of virtual participants attended the second annual Vermont Center for Cardiovascular and Brain Health (VCCBH) Symposium, held at the University of Vermont’s Davis Center June 2 to 3, 2022. The VCCBH, one of three National Institutes of Health Center of Biomedical Research Excellence (COBRE)-funded programs at UVM, is co-directed by Mary Cushman, M.D., M.Sc., professor and vice chair for emerging researchers in the Department of Medicine, and Mark Nelson, Ph.D., University Distinguished Professor and chair of the Department of Pharmacology.